New Data Links Common Diabetes Medication to Post-Infection Survival
A retrospective analysis conducted by researchers at Stanford University has revealed that adults with type 2 diabetes who were taking the common prescription drug metformin before contracting COVID-19 experienced a 39% lower risk of dying in the year following their infection compared to patients taking a different class of medication. The findings, published in the journal Diabetes, Obesity and Metabolism, suggest potential protective mechanisms that extend beyond the drug’s established role in blood sugar control, Fox News reported.
High blood sugar is known to weaken immune defenses, according to the Centers for Disease Control and Prevention. While metformin helps lower blood glucose and improves insulin sensitivity, researchers noted it remains unclear whether these metabolic effects fully account for the observed survival benefit. Investigators suggested the medication might also influence biological pathways regulating blood pressure and fluid balance, or help curb inflammation and viral replication during active infection.
Methodology and Patient Demographics
To evaluate long-term survival outcomes, the research team examined United States medical records covering 53,332 adults diagnosed with COVID-19 between October 2021 and November 2023. All analyzed individuals were aged 30 to 85 and had been prescribed either metformin or dipeptidyl peptidase-4 inhibitors (DPP4i) at least one month prior to their diagnosis. The vast majority of the cohort—50,965 patients—used metformin, while 2,367 patients relied on DPP4i medications.
Baseline characteristics showed demographic differences between the groups. Metformin users were younger on average, with a mean age of 60, compared to a mean age of 64 for patients taking DPP4i alternative drugs. After adjusting for age, gender, and other clinical variables through multivariable statistical modeling, the researchers observed a statistically significant survival advantage among metformin recipients over the subsequent 12-month period. Initial indications of a 13% reduction in long COVID symptoms among metformin users were ultimately found to be statistically non-significant upon further testing.
Context, Limitations, and Clinical Caution
The Stanford findings align with earlier investigations, including a University of Minnesota Medical School study indicating that prompt administration of metformin following a COVID-19 diagnosis reduced mortality and long COVID risks. However, because the Stanford project relied on observational medical records rather than a prospective clinical trial, authors emphasized that the design cannot establish direct causation.
Independent medical experts urged caution regarding clinical interpretation. Ziyad Al-Aly, a senior clinical epidemiologist at Washington University in St. Louis who was not involved with the study, explained that patients prescribed DPP4i medications typically present with more advanced age, compromised kidney function, or complex comorbidities that preclude metformin use. Consequently, underlying health disparities likely contributed to the higher observed mortality risk in the alternative medication group. Furthermore, researchers lacked comprehensive documentation regarding patient vaccination histories.
“This is not enough evidence to change treatment,” Al-Aly cautioned. “People take a DPP-4 inhibitor because they need it to control their diabetes, usually because metformin was not enough or was not an option for them. No doctor is choosing between these two drugs for the same patient. The comparison in this study is not a real choice in any clinic. If you take either drug, do not change it because of this study.”